Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: What are the long-term health-related quality-of-life outcomes?

Amy R. Perwien, Christopher J Kratochvil, Douglas E. Faries, Brigette S. Vaughan, Thomas Spencer, Ronald T. Brown

Research output: Contribution to journalArticle

59 Citations (Scopus)

Abstract

Objective: Numerous investigations have examined the efficacy of pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) in children. However, relatively few studies have addressed the impact of treatment on long-term subjective, psychosocial outcomes, such as health-related quality of life (HRQL). This study examines the long-term effects of pharmacological treatment with atomoxetine on HRQL in children and adolescents with ADHD. Methods: Participants included 6- to 17-year-old children and adolescents (n = 912) with ADHD enrolled in a 24-month, multicenter, open-label trial of atomoxetine. Outcomes included clinician ratings of ADHD, parent ratings of ADHD, and a widely used measure of HRQL (The Child Health Questionnaire (CHQ)). Treatment response rates were calculated based on a CHQ improvement of at least 1 standard error of measurement. Results: Significant improvements in HRQL were found following both acute and long-term treatment for psychosocial but not physical health. Of participants who completed treatment (n = 312 or 34.2% of those enrolled), 81% responded to acute treatment and 78% responded to long-term treatment. Improvements noted after acute treatment were maintained during long-term treatment with the majority of participants (86%) continuing to respond to treatment. Conclusions: Atomoxetine is associated with improvements in HRQL, and the improvements are generally stable over time.

Original languageEnglish (US)
Pages (from-to)713-724
Number of pages12
JournalJournal of Child and Adolescent Psychopharmacology
Volume16
Issue number6
DOIs
StatePublished - Dec 2006

Fingerprint

Attention Deficit Disorder with Hyperactivity
Quality of Life
Therapeutics
Atomoxetine Hydrochloride
Pharmacology
Quality Improvement
Health

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder : What are the long-term health-related quality-of-life outcomes? / Perwien, Amy R.; Kratochvil, Christopher J; Faries, Douglas E.; Vaughan, Brigette S.; Spencer, Thomas; Brown, Ronald T.

In: Journal of Child and Adolescent Psychopharmacology, Vol. 16, No. 6, 12.2006, p. 713-724.

Research output: Contribution to journalArticle

@article{9b4935aabda34100b58d7349abb1163a,
title = "Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: What are the long-term health-related quality-of-life outcomes?",
abstract = "Objective: Numerous investigations have examined the efficacy of pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) in children. However, relatively few studies have addressed the impact of treatment on long-term subjective, psychosocial outcomes, such as health-related quality of life (HRQL). This study examines the long-term effects of pharmacological treatment with atomoxetine on HRQL in children and adolescents with ADHD. Methods: Participants included 6- to 17-year-old children and adolescents (n = 912) with ADHD enrolled in a 24-month, multicenter, open-label trial of atomoxetine. Outcomes included clinician ratings of ADHD, parent ratings of ADHD, and a widely used measure of HRQL (The Child Health Questionnaire (CHQ)). Treatment response rates were calculated based on a CHQ improvement of at least 1 standard error of measurement. Results: Significant improvements in HRQL were found following both acute and long-term treatment for psychosocial but not physical health. Of participants who completed treatment (n = 312 or 34.2{\%} of those enrolled), 81{\%} responded to acute treatment and 78{\%} responded to long-term treatment. Improvements noted after acute treatment were maintained during long-term treatment with the majority of participants (86{\%}) continuing to respond to treatment. Conclusions: Atomoxetine is associated with improvements in HRQL, and the improvements are generally stable over time.",
author = "Perwien, {Amy R.} and Kratochvil, {Christopher J} and Faries, {Douglas E.} and Vaughan, {Brigette S.} and Thomas Spencer and Brown, {Ronald T.}",
year = "2006",
month = "12",
doi = "10.1089/cap.2006.16.713",
language = "English (US)",
volume = "16",
pages = "713--724",
journal = "Journal of Child and Adolescent Psychopharmacology",
issn = "1044-5463",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder

T2 - What are the long-term health-related quality-of-life outcomes?

AU - Perwien, Amy R.

AU - Kratochvil, Christopher J

AU - Faries, Douglas E.

AU - Vaughan, Brigette S.

AU - Spencer, Thomas

AU - Brown, Ronald T.

PY - 2006/12

Y1 - 2006/12

N2 - Objective: Numerous investigations have examined the efficacy of pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) in children. However, relatively few studies have addressed the impact of treatment on long-term subjective, psychosocial outcomes, such as health-related quality of life (HRQL). This study examines the long-term effects of pharmacological treatment with atomoxetine on HRQL in children and adolescents with ADHD. Methods: Participants included 6- to 17-year-old children and adolescents (n = 912) with ADHD enrolled in a 24-month, multicenter, open-label trial of atomoxetine. Outcomes included clinician ratings of ADHD, parent ratings of ADHD, and a widely used measure of HRQL (The Child Health Questionnaire (CHQ)). Treatment response rates were calculated based on a CHQ improvement of at least 1 standard error of measurement. Results: Significant improvements in HRQL were found following both acute and long-term treatment for psychosocial but not physical health. Of participants who completed treatment (n = 312 or 34.2% of those enrolled), 81% responded to acute treatment and 78% responded to long-term treatment. Improvements noted after acute treatment were maintained during long-term treatment with the majority of participants (86%) continuing to respond to treatment. Conclusions: Atomoxetine is associated with improvements in HRQL, and the improvements are generally stable over time.

AB - Objective: Numerous investigations have examined the efficacy of pharmacological treatment for attention-deficit/hyperactivity disorder (ADHD) in children. However, relatively few studies have addressed the impact of treatment on long-term subjective, psychosocial outcomes, such as health-related quality of life (HRQL). This study examines the long-term effects of pharmacological treatment with atomoxetine on HRQL in children and adolescents with ADHD. Methods: Participants included 6- to 17-year-old children and adolescents (n = 912) with ADHD enrolled in a 24-month, multicenter, open-label trial of atomoxetine. Outcomes included clinician ratings of ADHD, parent ratings of ADHD, and a widely used measure of HRQL (The Child Health Questionnaire (CHQ)). Treatment response rates were calculated based on a CHQ improvement of at least 1 standard error of measurement. Results: Significant improvements in HRQL were found following both acute and long-term treatment for psychosocial but not physical health. Of participants who completed treatment (n = 312 or 34.2% of those enrolled), 81% responded to acute treatment and 78% responded to long-term treatment. Improvements noted after acute treatment were maintained during long-term treatment with the majority of participants (86%) continuing to respond to treatment. Conclusions: Atomoxetine is associated with improvements in HRQL, and the improvements are generally stable over time.

UR - http://www.scopus.com/inward/record.url?scp=33846583296&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846583296&partnerID=8YFLogxK

U2 - 10.1089/cap.2006.16.713

DO - 10.1089/cap.2006.16.713

M3 - Article

C2 - 17201615

AN - SCOPUS:33846583296

VL - 16

SP - 713

EP - 724

JO - Journal of Child and Adolescent Psychopharmacology

JF - Journal of Child and Adolescent Psychopharmacology

SN - 1044-5463

IS - 6

ER -